These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 10090136

  • 1. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
    Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G.
    J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
    Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A.
    Pituitary; 1999 Jun; 1(2):115-20. PubMed ID: 11081189
    [Abstract] [Full Text] [Related]

  • 5. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M.
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
    Ambrosio MR, Franceschetti P, Bondanelli M, Doga M, Maffei P, Baldelli R, Tamburrano G, Sicolo N, Giustina A, degli Uberti EC.
    Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
    [Abstract] [Full Text] [Related]

  • 7. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Vieni A, Trimarchi F.
    Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
    [Abstract] [Full Text] [Related]

  • 8. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G.
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F.
    Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
    Chanson P, Leselbaum A, Blumberg J, Schaison G.
    Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 15. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M, Gebbie J, Kendall-Taylor P.
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P.
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [Abstract] [Full Text] [Related]

  • 18. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
    Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R.
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759
    [Abstract] [Full Text] [Related]

  • 19. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M.
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [Abstract] [Full Text] [Related]

  • 20. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months.
    Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, Scarpa R, Smaltino F, Lombardi G.
    Clin Endocrinol (Oxf); 1999 Nov; 51(5):611-8. PubMed ID: 10594522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.